Current and future disease progression of the chronic HCV population in the United States

Martin Zalesak1, Kevin Francis, Alex Gedeon

  • 1Trinity Partners, LLC, Waltham, Massachusetts, United States of America. zalesakm@trinitypartners.com

Plos One
|May 25, 2013
PubMed

Insights

Chronic hepatitis C virus (HCV) infection significantly impacts the "baby boomer" generation, driving advanced liver disease (AdvLD) progression. Urgent diagnosis and treatment are crucial to interrupt disease advancement in this population.

Area of Science:

  • Hepatology
  • Public Health
  • Epidemiology

Background:

  • Chronic hepatitis C virus (HCV) infection is a leading cause of advanced liver disease (AdvLD), including cirrhosis and liver cancer.
  • The
  • baby boomer
  • generation (born 1945-1964) represents a disproportionately large segment of the HCV-infected population and associated healthcare costs.

Purpose of the Study:

  • To determine historical rates of HCV patient progression to AdvLD.
  • To project the prevalence of AdvLD through 2015.
  • To identify key demographic groups driving AdvLD progression and costs.

Main Methods:

  • Utilized National Health and Nutrition Examination Surveys for 2008 US chronic HCV prevalence.
  • Analyzed 2007-2009 IMS LifeLink and CMS Medicare claims data for disease progression and costs.
  • Developed a projection model for AdvLD prevalence through 2015, incorporating diagnosed and undiagnosed patients.

Main Results:

  • The diagnosed chronic HCV population increased from 983,000 to 1.19 million between 2007-2009.
  • Patients born 1945-1964 constituted 75.0% of all HCV patients, 83.7% of AdvLD patients, and 79.2% of costs in 2009.
  • AdvLD population projected to grow from 195,000 (2008) to 601,000 (2015), with 73.5% of new cases from undiagnosed individuals.

Conclusions:

  • HCV is primarily a disease affecting the
  • baby boomer
  • population, with significant AdvLD progression and associated costs.
  • A substantial increase in AdvLD is projected, driven by both diagnosed and undiagnosed HCV cases.
  • Immediate strategies for HCV diagnosis and treatment are essential to mitigate AdvLD progression, particularly in the baby boomer cohort.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...